Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 9/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 10/20 | 0.54 |
| ▸ | KDR | P35968 | 4/20 | 0.54 |
| ▸ | FLT1 | P17948 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2915850 | 0.84 | IGF1R (0.70) | FLT3IGF1RAURKAKDRFLT1 | |
| SCHEMBL2919885 | 0.84 | STK25 (0.46) | AURKAALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2925281 | 0.80 | AURKA (0.73) | FLT3AURKAKDRFLT1AURKB | |
| SCHEMBL2923174 | 0.80 | KDM4E (0.53) | IGF1RALDH1A1SMN1; SMN2 | |
| SCHEMBL2918892 | 0.80 | AURKA (0.72) | FLT3AURKAKDRFLT1AURKB | |
| SCHEMBL2922374 | 0.79 | STK25 (0.46) | IGF1RAURKAALDH1A1SMN1; SMN2 | |
| SCHEMBL2921839 | 0.78 | CCNA2 (0.47) | AURKAALDH1A1SMN1; SMN2AURKBNPC1 | |
| SCHEMBL2923683 | 0.78 | IGF1R (0.47) | IGF1RALDH1A1SMN1; SMN2 | |
| SCHEMBL2915055 | 0.78 | ALDH1A1 (0.49) | AURKAALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2924780 | 0.77 | STK25 (0.46) | IGF1RAURKAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320531-B1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PFIZER ITALIA SRL (IT) | 2010-09-08 | — | — | EP | claimed |
| US-7541354-B2 | Bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | claimed |
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2003-09-11 | — | — | US | claimed |
| US-8273765-B2 | Bicyclo-pyrazoles and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2012-09-25 | — | — | US | disclosed |
| EP-1320531-B1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PFIZER ITALIA SRL (IT) | 2010-09-08 | — | — | EP | disclosed |
| US-20090221632-A1 | Bicyclo-Pyrazoles and Pharmaceutical Compositions Comprising Them | PFIZER ITALIA S.R.L. (IT) | 2009-09-03 | — | — | US | disclosed |
| US-7541354-B2 | Bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | disclosed |
| US-7531531-B2 | Method of treating diseases associated with altered kinase activity with bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-05-12 | — | — | US | disclosed |
| US-20070191386-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-08-16 | — | — | US | disclosed |
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191386-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K19, MAP3K1 | FLT3 437/4885IGF1R 1793/4885AURKA 347/4885 |
| US-20090221632-A1 | Bicyclo-Pyrazoles and Pharmaceutical Compositions Comprising Them | MAP3K20, PLK2, PRKAA1 | FLT3 605/4885IGF1R 2979/4885AURKA 600/4885 |
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K19, MAP3K1 | FLT3 437/4885IGF1R 1793/4885AURKA 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.